The global plus-size clothing market is projected to reach $395.60 billion by 2034, even as GLP-1 medications—marketed heavily to women over 50—pose new risks for those with undiagnosed eating disorders. On May 23, 2026, doctors and industry experts warn that the pharmaceutical industry’s push for weight-loss drugs may be exacerbating a crisis among older women, a demographic long overlooked in eating disorder research.
A Crisis Hidden in Plain Sight
cluster (priority): The Curvy Fashionista
The 53-year-old woman who walked into a doctor’s office last month wasn’t looking for help with an eating disorder. She was there for a routine physical, but when the conversation turned to weight-loss medications, she admitted she didn’t even know why she wanted them—only that she’d seen the ads everywhere. “I don’t really know,” she told her physician. “But I keep seeing these ads, and everyone’s talking about it. I feel like maybe I should try it.”
Her hesitation wasn’t unusual. According to a recent KFF poll, one in eight American adults is now taking a GLP-1 drug, with the 50–64 age group reporting the highest usage. Yet the same medications that promise effortless weight loss carry a dangerous side effect for some: they can trigger or worsen eating disorders, particularly in women over 50—a population where disordered eating is often missed entirely.
The problem isn’t just that doctors fail to recognize the signs. It’s that the cultural narrative around aging, weight, and pharmaceutical solutions has created a perfect storm. For decades, diet culture has framed weight loss as the ultimate fix for self-worth, but now, with GLP-1s like semaglutide and tirzepatide dominating headlines and social media, the stakes are higher. “We’re trained to miss eating disorders in older women,” one physician wrote in a recent analysis. “In medical school, the eating disorder cases we studied were almost always young white women. The textbooks showed underweight teenagers.” The result? A generation of women who’ve spent years battling body image issues, only to find themselves targeted by an industry selling a quick fix—one that could unravel decades of hard-won stability.
The GLP-1 Paradox: Weight Loss as a New Trigger
cluster (priority): The Nation
GLP-1 medications weren’t designed for eating disorder patients, but that hasn’t stopped them from being prescribed—or sought out—by those already vulnerable. A 2024 study in the *International Journal of Eating Disorders* found that these drugs could exacerbate or contribute to the development of disordered eating, particularly in individuals with a history of restrictive behaviors. The mechanism is simple: GLP-1s suppress appetite, reduce food cravings, and slow digestion. For someone with anorexia or bulimia, that can feel like a godsend—until it becomes impossible to eat normally again.
Stevee Williams, a Houston restaurant manager diagnosed with anorexia at 17, knows this firsthand. She was preparing for her sister’s wedding when anxieties resurfaced about her body in a bridesmaid dress. The thought of medication crossed her mind—not as a solution, but as a potential trap. “I’ve been approximately 30 percent fatter than I should have been,” she reflected, echoing the internalized shame many women carry. “But I also know what happens when I try to control my weight too tightly.” For Williams, the fear wasn’t just about the dress. It was about the cycle of restriction and guilt that had defined her relationship with food for decades.
The irony? GLP-1s are being marketed as a way to break that cycle. Pharmaceutical companies and social media influencers have turned weight loss into a status symbol, framing appetite suppression as empowerment. But for those with underlying eating disorders, the drugs can become a new crutch—one that reinforces the very behaviors they’re supposed to overcome.
The Plus-Size Market’s Resilience vs. the GLP-1 Panic
GLP-1s Explained: Breaking the Weight Loss Stigma
While doctors and patients grapple with the risks, the fashion industry is watching with a mix of alarm and skepticism. The global plus-size clothing market is valued at $244.85 billion in 2025 and is projected to hit $395.60 billion by 2034—a trajectory that has thrived *alongside* diet culture, not despite it. “We have been here before,” one industry executive wrote in a recent op-ed. “Fen-Phen. Phen-Phen. Atkins. Keto. Every magazine cover promising a new body by summer since 1987.” Yet through every fad, the plus-size market didn’t just survive—it grew.
The question now is whether GLP-1s will be different. After all, this isn’t just another diet trend. These are prescription medications, heavily advertised and widely accessible. “Right now, approximately 10 million Americans are on GLP-1 medications,” the executive noted. “That’s a lot of women who may be skipping meals, restricting calories, or developing new patterns of disordered eating—all while their doctors assume they’re just ‘managing their weight.’”
The risk isn’t that the plus-size market will collapse. It’s that the women who rely on it—the same women who’ve been told for decades that their bodies are problems to fix—will find themselves caught in a new cycle of shame and restriction. “The smartest brands are finally acknowledging what the rest of us have known for years,” the executive continued. “You cannot lead a plus-size brand off an outdated playbook written for a consumer who was never your customer to begin with.” The challenge now is whether the pharmaceutical industry—and the doctors prescribing these drugs—will do the same.
The Older Woman’s Eating Disorder: A Diagnosis Delayed
cluster (priority): news.google.com
The most alarming gap isn’t in the data. It’s in the diagnosis. When most people think of eating disorders, they picture teenagers. But research shows that 13 percent of women over 50 exhibit symptoms of disordered eating—a number that’s rising as menopause, metabolic shifts, and societal pressure converge. “You’re dealing with hot flashes, sleep problems, and brain fog,” one physician explained. “The overwhelm alone could trigger disordered eating, especially if you’ve battled it before.”
The problem is that doctors often don’t recognize the signs. A woman in her 60s who skips meals might be dismissed as managing her blood sugar. A manopausal patient who restricts calories to “stay in shape” might be told she’s just being proactive. “We’re trained to miss eating disorders in older women,” the physician wrote. “The ‘classic presentation’ we learned was anorexia in a high-achieving college student or bulimia in someone in their 20s.”
That blind spot has deadly consequences. Eating disorders have the highest mortality rate of any mental illness, yet older adults are far less likely to receive treatment. GLP-1s add another layer: they can mask the symptoms of an eating disorder, making it even harder to spot. A patient who suddenly loses weight on medication might be praised for their discipline—never mind that they’re also developing dangerous restrictive behaviors.
What Comes Next: Policy, Prescribing, and Public Awareness
So what happens now? The first step is better screening. The American Psychiatric Association has long recommended that doctors assess for eating disorder risk in all patients considering weight-loss medications, but compliance is inconsistent. “To us, this is hard to admit,” one expert wrote, “but the truth is, we’re trained to miss eating disorders in older women.” Changing that requires education—not just for physicians, but for patients, too.
Pharmaceutical companies must also take responsibility. While GLP-1s carry black-box warnings about potential risks to patients with a history of eating disorders, the marketing—celebrity endorsements, before-and-after transformations, the relentless message that thinner is better—has created a cultural permission slip for restriction. “Brands spend hundreds of millions promoting GLP-1s,” one physician noted. “The message lands especially hard on women my age and older. We’re told that aging bodies are problems to solve.”
The fashion industry has a role to play, too. As the plus-size market continues to grow, brands must resist the urge to frame weight loss as the ultimate goal. “The plus-size consumer wants connection. Community. To be seen,” one executive argued. “Not just to be sold to.” That means moving beyond the outdated playbook of diet culture and acknowledging that body diversity isn’t just about size—it’s about health, self-worth, and the right to exist without judgment.
For now, the most urgent task is ensuring that women like the 53-year-old in the exam room aren’t left to navigate these risks alone. “I don’t really know,” she said, “but I keep seeing these ads.” The question is whether anyone will listen—and whether the system is prepared to help when the answer isn’t just about weight loss, but about healing.
For anyone considering GLP-1 medications, consult a healthcare provider to discuss potential risks, including eating disorder triggers. If you or someone you know is struggling with disordered eating, resources are available through organizations like the National Eating Disorders Association.
